Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis

Objective. - .In this study, we investigated the potential of meloxicam (MLX) developed as transferosomal gel as a novel lipidic drug delivery system to address osteoarthritis (OTA), a degenerative joint disease that causes pain and stiffness. By incorporating meloxicam into a transferosomal gel, our aim was to provide a targeted and efficient delivery system capable of alleviating symptoms and slowing down the progression of OTA. Material and methods. - Classical lipid film hydration technique was utilized to formulate different transferosomal formulations. Different transferosomal formulations were prepared by varying the molar ratio of phospholipon-90H (phosphodylcholine) to DSPE (50:50, 60:40, 70:30, 80:20, and 90:10) and per batch, 80 mg of total lipid was used. The quality control parameters such as entrapment efficiency, particle size and morphology, polydispersity and surface electric charge, in vitro drug release, ex vivo permeation and stability were measured. Results. - The optimized transferosomal formulations revealed a small vesicle size (121 +/- 12 nm) and greater MLX entrapment (68.98 +/- 2.3%). Transferosomes mediated gel formulation MLX34 displayed pH (6.3 +/- 0.2), viscosity (6236 +/- 12.3 cps), spreadability (13.77 +/- 1.77 gm.cm/sec) and also displayed sustained release pattern of drug release (81.76 +/- 7.87% MLX released from Carbopol-934 gel matrix in 24 h). MLX34 revealed close to substantial antiinflammatory response, with similar to 81% inhibition of TNF-a in 48 h. Physical stability analysis concluded that refrigerator temperature was the preferred temperature to store transferosomal gel. Conclusion. - MLX loaded transferosomes containing gel improved the skin penetration and therefore resulted into increased inhibition of TNF-a level. (c) 2024 Academie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights reserved.